Form 4: RA Capital Management Discloses Climb Bio Stake

RA Capital Management, L.P. and its affiliated funds have reported changes in beneficial ownership related to Climb Bio, Inc. (CLYM), including the acquisition of stock options.

Summary

• RA Capital Management, L.P. and several of its affiliated funds (RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P.) have filed a Form 4 with the SEC.
• The filing details transactions and beneficial ownership related to Climb Bio, Inc. (CLYM).
• Specifically, it reports a stock option grant to Breanna Celebi, an Analyst at RA Capital Management, for 70,284 shares of common stock with an exercise price of $13.36, exercisable from June 29, 2026, to June 29, 2036.
• RA Capital Management, L.P. is identified as the investment manager for the funds involved.
• Peter Kolchinsky and Rajeev Shah are managing members of the general partner of the investment adviser.
• Breanna Celebi serves on the board of directors of Climb Bio, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of ownership changes and option grants rather than a report on company performance or strategic shifts.

Positives

• RA Capital Management and its funds are significant stakeholders, indicated by their 10% owner status and director representation.
• The acquisition of stock options suggests a potential for future value appreciation and alignment of interests.

Negatives

• The filing is a disclosure of changes in beneficial ownership, not a financial performance report, so direct financial negatives are not applicable.
• The disclaimer of beneficial ownership by RA Capital Management and its affiliates, except to the extent of their pecuniary interest, adds a layer of complexity to understanding direct control.

Risks

• The vesting of stock options is subject to Breanna Celebi's continued service through the vesting commencement date and subsequent vesting periods.
• The disclaimer of beneficial ownership by RA Capital Management and its affiliates means their direct control or interest in the securities may be limited to their pecuniary interest.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding Climb Bio's financial performance. The stock option grant implies a long-term perspective on the company's potential value.

Management Comments

• Breanna Celebi, an Analyst of the Adviser, serves on the Issuer's board of directors.
• Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for significant investors and insiders. RA Capital Management is a known active investor in the biotechnology and healthcare sectors, and their involvement with Climb Bio, Inc. suggests a strategic interest in the company's development pipeline or market position.

Related Party Transactions

• Breanna Celebi, an Analyst at RA Capital Management, holds stock options for the benefit of RA Capital funds, with any net proceeds offsetting advisory fees owed to RA Capital Management.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership changes and potential future dilution if options are exercised.
• Employees: Breanna Celebi's role as an Analyst and Director highlights the intersection of investment management and corporate governance.
• Creditors: No direct impact is indicated in this filing.

Next Steps

• Monitoring future transactions and disclosures by RA Capital Management and its affiliates related to Climb Bio, Inc.
• Observing the vesting and potential exercise of the reported stock options.

Key Dates

Keywords

Form 4, SEC Filing, RA Capital Management, Climb Bio, CLYM, Beneficial Ownership, Stock Options, Insider Trading, Director, 10% Owner